Member Info for Hurst10

Think we should get this clear, Zeus Capital healthcare team are concentrating on their corporate business in the UK and Euronext Brussels and Paris related business.

Avacta with their ongoing news flow , will no doubt early next year expand further on their proposed Nasdaq listing and the upcoming JP Morgan healthcare conference Jan 12-15th seems a very suitable platform to introduce triple A US brokers to be such book runners.

Nasdaq getting closer .

NY is indeed up early.

Management have shares and not to forget warrants and options .

Watch out for printed size buy orders lifting us into the mid 80', before a vey interesting afternoon!

1st : Today the American Association for Cancer Research® (AACR) released the inaugural AACR Pediatric Cancer Progress Report 2025. This first-of-its-kind report highlights how research is transforming outcomes for children and adolescents with cancer.

Lilly takes $15M stake in ABL Bio, bets up to $2.6B on its bispecifics.

+

Crispr (CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that was circulating on Monday. The interest may be from a US-based biopharma with a market cap of $100-$200 billion.

Crispr (CRSP) has a market cap of $5 billion.

Crispr (CRSP) is set to present at the Jefferies Global Healthcare Conference on Tuesday.

Interesting to see the M&A momentum picking up :

Pfizer out bidding Novo-Nordisk $10 bill

Lundbeck joining the bidding war for Avadel

Merck bidding $3 bill for Cidara Therapeutics

Makes current share price of Avacta quite irrelevant and with expected news flow will re rate Avacta significantly , with a target beyond anything we have seen before and off course breaking 12 mth highs later this afternoon.

👍perhaps difficult to buy back.

The market is trying to get enough stock for a strong opening am.

Very surprised if not size buyer print after hrs.

If we hold current bid into the close , we could have a lively kick off , RNS or not.

Our good friend Tempus will be talking AI and Precision Oncology.

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:00 AM ET.

Should be interesting and positive for the momentum in the sector.

MM's pre US opening, will find it difficult to make " price and size " at current levels and offer price will be overtaken by the bid ! Watch who will be on the bid !!'

Just a reminder that Jefferies is hosting their Biotech/ Healthcare conf. Next week.

With M&A picking up in Biotech , Avacta' s upcoming newsflow will certainly receive the attention the company deserves.

Looks like our Japanese friends is out shopping again!

No wonder they were interested in talking to CC.

Makes AVA032 even more interesting and a revaluation of the AVA portfolio looks likely again.

More bullish media coverages for our sector coming up!

This time tomorrow's Stifel Healthcare Conference ,November 11-13, New York.

AVCT not participating, suspecting too much going on.

Worth noting we have the UBS Global healthcare conference starting Monday 10/11 ( NY) and Jefferies London Healthcare Conference 17-20/11 with a dedicated Biotech/ Biopharma opening day . Plenty of news in the sector, volume will grow further.

Interesting order size last 30 min.

Just remember as always , keep telling us what you have a sell on and we will buy it . Works every time!

Worth remembering it is just over a year ago 21/11/24, that Avacta and Tempus entered strategic collaboration to advance AI-Driven Drug Development in Oncology. Quote from Tempus" we are thrilled to partner with Avacta in support of their efforts to bring game-changing new therapies to patients in need" .

Tempus has Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 downward. Revenue estimates have seen 7 upward revisions and 3 downward.

Tempus AI + 159% gain YTD.

Avacta and AI !

With Tempus 3rd Q results out next week and stock up 100% first year , worth reminding ourselves what the Scientific Officer of Tempus said when signing up with Avacta: This collaboration with Avacta is another example of our execution of that vision, and we are thrilled to partner with Avacta in support of their efforts to bring game-changing new therapies to patients in need."

Worth remembering we will have Jefferies hosting:

Monday, November 17 will mark the launch of a focused Biotech/Biopharma Kick-off Day, while November 18 – 20 will continue to feature the full spectrum of the healthcare industry – including biopharma, biotech, specialty pharma, medical technology, healthcare services, healthcare IT, and other key sub-sectors.

Look who is advising Novartis : GS

Novartis not finished yet

Let us hope Avacta makes it to a Nasdaq listing.

Worth asking CC on Wednesday on a guidance of time before we are crossing the pond.

Sorry if repeat :

Avidity Biosciences to be Acquired by Novartis AG for $12.0 Billion